Futures trading had markets showing mixed ahead of Thursday’s opening bell. The Dow Jones was called 9 points higher at 40,153, while the...
Big Tech firms are likely coming to the end of a trend in which they outperform market...
bluebird bio Inc (NASDAQ:BLUE), the gene therapy developer, is well-positioned to outperform...
Walt Disney Co (NYSE:DIS, ETR:WDP) will be able to ramp up its buyback programs, grow its...
"Management is doing things right; leadership is doing the right things." Famed business...
Merck & Co Inc (NYSE:MRK, ETR:6MK) shares traded more than 4% higher after it won US Food...
Psychedelics stocks traded higher on Thursday as investor optimism returned to the sector on the...
Nevis Brands (CSE:NEVI)' cannabis beverage product Major is now available for purchase in...
1606 Corp. (OTC:CBDW) said in March it plans to focus on growth through strategic partnerships...
Cannabis firms OrganiGram Holdings (TSX-V:OGI, NASDAQ:OGI) and Aurora Cannabis Inc (TSX:ACB,...
BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...